Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


22.05.2017

1 Ann Thorac Surg
1 Br J Cancer
2 Cancer Chemother Pharmacol
1 Cancer Lett
1 Cancer Res
2 Chest
3 Clin Lung Cancer
4 Clin Nucl Med
1 Epidemiology
1 Int J Cancer
1 J Clin Oncol
1 J Nucl Med
4 J Thorac Cardiovasc Surg
2 J Thorac Oncol
2 Lancet
1 Lancet Oncol
2 Mol Cancer Ther
3 N Engl J Med
1 Oncogene
2 Oncologist


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. MEHTA K, Moravcikova E, McFall D, Luketich JD, et al
    The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2017 May 9. pii: S0003-4975(17)30205.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  3. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Text format     Abstract available

  4. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Text format     Abstract available


    Cancer Lett

  5. ZHANG J, Kong L, Jiao Q, Li M, et al
    Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead.
    Cancer Lett. 2017 May 16. pii: S0304-3835(17)30311.
    PubMed     Text format     Abstract available


    Cancer Res

  6. YE M, Zhang Y, Zhang X, Zhang JB, et al
    Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
    Cancer Res. 2017 May 18. pii: canres.3470.2016.
    PubMed     Text format     Abstract available


    Chest

  7. KHUNGER M, Rakshit S, Pasupuleti V, Hernandez AV, et al
    Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A Systematic Review and Meta-analysis of trials.
    Chest. 2017 May 9. pii: S0012-3692(17)30882-6. doi: 10.1016/j.chest.2017.
    PubMed     Text format     Abstract available

  8. CHEE J, Robinson BW, Holt RA, Creaney J, et al
    Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.
    Chest. 2017;151:891-897.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  9. GANTI AK, Hirsch FR, Wynes MW, Ravelo A, et al
    Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.
    Clin Lung Cancer. 2017 Apr 26. pii: S1525-7304(17)30115.
    PubMed     Text format     Abstract available

  10. GIULIANI J, Bonetti A
    Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.
    Clin Lung Cancer. 2017 Apr 23. pii: S1525-7304(17)30112.
    PubMed     Text format    

  11. DAHELE M, Damhuis RA
    Relationship Between Tumor Location and Outcome in Patients With Early-Stage Lung Cancer.
    Clin Lung Cancer. 2017 Apr 23. pii: S1525-7304(17)30110.
    PubMed     Text format    


    Clin Nucl Med

  12. ABUBAKAR S, Amoako YA, Kotze T, Tag N, et al
    Source of Ectopic ACTH Secretion Easily Identified by 68Ga DOTANOC PET/CT.
    Clin Nucl Med. 2017 Jan 16. doi: 10.1097/RLU.0000000000001541.
    PubMed     Text format     Abstract available

  13. SAVELLI G, Bna C, Zambelli C, Illuminati S, et al
    An 111In-Pentetreotide Positive Sclerosing Pneumocytoma.
    Clin Nucl Med. 2017;42:282-284.
    PubMed     Text format     Abstract available

  14. GROE HOKAMP N, Kobe C, Linzenich E, Maintz D, et al
    Solitary PSMA-Positive Pulmonary Metastasis in Biochemical Relapse of Prostate Cancer.
    Clin Nucl Med. 2017;42:406-407.
    PubMed     Text format     Abstract available

  15. MAPELLI P, Incerti E, Fallanca F, Bettinardi V, et al
    Concomitant Lung Cancer and Gastrointestinal Stromal Tumor: First Report of Hypoxia Imaging With 18F-FAZA PET/CT.
    Clin Nucl Med. 2017 May 19. doi: 10.1097/RLU.0000000000001704.
    PubMed     Text format     Abstract available


    Epidemiology

  16. GRELLIER J, Atkinson W, Berard P, Bingham D, et al
    Risk of lung cancer mortality in nuclear workers from internal exposure to alpha particle-emitting radionuclides.
    Epidemiology. 2017 May 17. doi: 10.1097/EDE.0000000000000684.
    PubMed     Text format     Abstract available


    Int J Cancer

  17. XIE K, Chen M, Zhu M, Wang C, et al
    A polymorphism in miR-1262 regulatory region confers the risk of lung cancer in Chinese population.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30788.
    PubMed     Text format     Abstract available


    J Clin Oncol

  18. LIM SM, Kim HR, Lee JS, Lee KH, et al
    Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
    J Clin Oncol. 2017 May 18:JCO2016713701. doi: 10.1200/JCO.2016.71.3701.
    PubMed     Text format     Abstract available


    J Nucl Med

  19. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  20. WEKSLER B
    One in every 14 patients with early-stage lung cancer is not being treated!
    J Thorac Cardiovasc Surg. 2017 Apr 24. pii: S0022-5223(17)30850.
    PubMed     Text format    

  21. BURT BM
    Incompletely resected non-small cell lung cancer: Do we know how to handle a positive margin?
    J Thorac Cardiovasc Surg. 2017 Apr 12. pii: S0022-5223(17)30689.
    PubMed     Text format    

  22. BERRY MF
    Evidence for resection of sarcoma pulmonary metastases: More, but better?
    J Thorac Cardiovasc Surg. 2017 Apr 7. pii: S0022-5223(17)30658.
    PubMed     Text format    

  23. HOANG CD
    Protein-based prognostic biomarkers in lung cancer: Promise or pitfall?
    J Thorac Cardiovasc Surg. 2017 Apr 23. pii: S0022-5223(17)30851.
    PubMed     Text format    


    J Thorac Oncol

  24. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Text format     Abstract available

  25. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Text format     Abstract available


    Lancet

  26. GAINOR JF, Shaw AT
    J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
    Lancet. 2017 May 10. pii: S0140-6736(17)31074.
    PubMed     Text format    

  27. HIDA T, Nokihara H, Kondo M, Kim YH, et al
    Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Lancet. 2017 May 10. pii: S0140-6736(17)30565.
    PubMed     Text format     Abstract available


    Lancet Oncol

  28. DAS M
    Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30342.
    PubMed     Text format    


    Mol Cancer Ther

  29. RAIMBOURG J, Joalland MP, Cabart M, de Plater L, et al
    Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.
    Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017.
    PubMed     Text format     Abstract available

  30. ROSS KC, Andrews AJ, Marion CD, Yen TJ, et al
    Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells.
    Mol Cancer Ther. 2017 May 12. pii: molcanther.0798.2016.
    PubMed     Text format     Abstract available


    N Engl J Med


  31. Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed     Text format    

  32. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed     Text format    

  33. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed     Text format    


    Oncogene

  34. CHOI EJ, Jung BJ, Lee SH, Yoo HS, et al
    A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncologist

  35. MIYAUCHI E, Inoue A, Usui K, Sugawara S, et al
    Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
    Oncologist. 2017 May 19. pii: theoncologist.2017-0059.
    PubMed     Text format     Abstract available

  36. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Oncologist. 2017 May 15. pii: theoncologist.2016-0331.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: